Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a mendelian randomization analysis

Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with the risk of coronary heart disease (CHD), but randomized trials of several therapies that reduce Lp(a) levels by 25% to 35% have not provided any evidence that lowering Lp(a) level reduces CHD risk.To...

Full description

Bibliographic Details
Main Authors:	Burgess, S, Ference, BA, Staley, JR, Freitag, DF, Mason, AM, Nielsen, SF, Willeit, P, Young, R, Surendran, P, Karthikeyan, S, Bolton, TR, Peters, JE, Kamstrup, PR, Tybjærg-Hansen, A, Benn, M, Langsted, A, Schnohr, P, Vedel-Krogh, S, Kobylecki, CJ, Ford, I, Packard, C, Trompet, S, Jukema, JW, Sattar, N, Di Angelantonio, E, Saleheen, D, Howson, JMM, Nordestgaard, BG, Butterworth, AS, Danesh, J, Key, T, European Prospective Investigation Into Cancer And Nutrition-Cardiovascular Disease (EPIC-CVD) Consortium
Format:	Journal article
Language:	English
Published:	American Medical Association 2018

Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a mendelian randomization analysis

Similar Items